Brentuximab vedotin (BV) is a CD30-targeted antibody conjugated with auristatin E that has shown high efficacy in relapsed HL and multiple T cell lymphomas (30–33). The gene discussed is TNFRSF8; the disease is Hodgkins lymphoma.